Skip to main content

04-06-2019 | Castration-sensitive prostate cancer | ASCO 2019 | Article

Researcher comment: OS boost with enzalutamide in metastatic CSPC setting

Conference coverage direct to your inbox

Christopher Sweeney presents the main findings of the ENZAMET trial, which evaluated the impact of supplementing androgen deprivation therapy with enzalutamide in men with advanced castration-sensitive prostate cancer (3:10).

Back to the conference hub​​​​​​​

Related topics

More on this topic

Image Credits